Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000104.xml
Zentralbl Chir 2021; 146(S 01): S49
DOI: 10.1055/s-0041-1733366
DOI: 10.1055/s-0041-1733366
Abstracts
V-122 Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): First Real-World Evidence of NSCLC Stage II and III in Germany - AIO-TRK-0315
Hintergrund
CRISP is a non-interventional, prospective, multi-center clinical research platform whose aim is to understand the treatment reality of patients (pts) with lung carcinoma in Germany. Here we present first data of pts diagnosed with NSCLC in stages II or III (IIIB/C if treated with curative intent).
Publication History
Article published online:
06 September 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart,
Germany